We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter Life Sciences Highlights Clinical Flow Cytometry Portfolio

By LabMedica International staff writers
Posted on 31 Jul 2018
Beckman Coulter Life Sciences (Brea, CA, USA) highlighted its expanding portfolio of clinical flow cytometry solutions, including its latest innovations ranging from portfolio extensions to its range of single-color antibodies, high quality IVD panels and customized solutions, at the 70th American Association of Clinical Chemistry (AACC) Annual Scientific Meeting and Clinical Laboratory Expo (CLE) in Chicago, USA.

Beckman Coulter Life Sciences develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. More...
Its latest innovations highlighted at AACC 2018 included ClearLLab Casebook 5C, a step by step illustrative resource into complex pattern recognition for leukemia and certain lymphomas, using the ClearLLab panel of reagents; enhanced portfolio of single color CE-IVD and analyte-specific reagents (ASR); DURA Innovations dry reagent technology, available in a range of services and reagents including ClearLLab; and the company’s expanded external business resources - the LUCID custom design and cocktailing services and RESOURCE contract manufacturing services, both of which are underpinned by DURA Innovations.

The ClearLLab5C Casebook provides the clinical history of 16 patients, illustrating the progressive analysis of flow cytometric immunophenotyping data by means of numerous color-coded illustrated scatter plots. These first assess and then assign the cells before giving a detailed characterization of the aberrant population according to the presence or absence of antigens. It includes patients with characteristic findings typical of various lymphoid and myeloid neoplasms as well as those with clinical and/or laboratory findings suggesting an underlying neoplastic process, but in which no immunophenotypic abnormality is identified. Specimen types include peripheral blood, bone marrow, and lymph nodes. Each case concludes with an assessment of the immunophenotypic findings as well as potential pitfalls.

“By standardizing the process, ClearLLab has removed one of the limitations to flow cytometry gaining its place in the routine lab, removing the need for a lab to manually prepare and design panels, a time- consuming process,” said Dr. Mario Koksch, Vice President and General Manager of Beckman Coulter’s Cytometry Business Unit.

At AACC 2018, Beckman Coulter also highlighted its largest portfolio of single color CE-IVD and ASR conjugated antibodies. The company manufactures all its single color reagents under Good Manufacturing Practices (GMP) in facilities that adhere to the highest standards in the industry. Their tandem dye stability and lot-to-lot consistency ensure reproducible and reliable results.

Also highlighted at the event was Beckman Coulter’s DURA Innovations dry, unitized reagent assays that help laboratories to simplify sample preparation, by reducing preparation time and reagent waste. The company’s panel design experts have created a range of multi-color pre-formulated options to standardize flow cytometry workflows, whether used for clinical research or research studies. The panels include single color compensation tubes for enhanced accuracy in off the shelf products and LUCID solutions. These solutions are at the heart of the company’s expanded external business resources, delivering off-the-shelf reagents, customized solutions through LUCID custom design and cocktailing services (CDS), or in bulk through RESOURCE contract manufacturing services (CMS).

“Dura Innovations solutions deliver greater efficiency while ensuring they have confidence in delivering high quality, reproducible results – and that that they will be compliant with current exacting standards,” said Dr. Koksch. “Through the technology of DURA Innovations, and the resources we provide, we are able to demonstrate that producing in-house cocktails is no longer the most efficient way to save time and costs. In contrast, we are able to offer customers choice and flexibility, tailoring a service exactly to their requirements, from small quantities to high volume throughput demands.”


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myocardial Infarction Test
Quidel Triage Cardio3 Panel
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.